The role of positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose in the diagnosis of soft tissue sarcomas
E. S. Koroleva,
A. I. Pronin,
A. I. Mikhailov,
A. A. Odzharova,
E. A. Sushentsov,
B. Y. Bokhyan,
A. S. Krylov https://doi.org/10.17650/2782-3687-2022-14-4-63-70
Abstract
Soft tissue sarcoma are here, heterogeneous malignant neoplasms that present difficulties in diagnosis, treatment and follow-up. High-quality diagnostic planning allows timely decision-making on further tactics of patient management in a particular case. Positron emission tomography with a biological analogue of glucose – 18F-fluorodeoxyglucose, combined with computed tomography, is an imaging tool that measures the metabolic activity of a tumor and is increasingly used in clinical practice to assess primary tumor tissue, staging, monitoring the effectiveness of treatment and as a method of early detection of relapses. This literature review is aimed at evaluating the usefulness of positron emission tomography combined with computed tomography at different stages of diagnostic control in patients with soft tissue sarcomas.
About the Authors
E. S. Koroleva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
A. I. Pronin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
A. I. Mikhailov
S.P. Botkin City Clinical Hospital of the Ministry of Health of Russia;
Russian Federation
Russian Federation
5 2nd Botkinskij proezd, Moscow 125284
A. A. Odzharova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
E. A. Sushentsov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
B. Y. Bokhyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
A. S. Krylov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
References
1. Rebecca L., Siegel M.H., Kimberly D. et al. Cancer statistics, 2022. CA Cancer J Clini 2022;72(1):7–33. DOI: 10.3322/caac.21708
2. The state of oncological care for the population of Russia in 2021. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of “NMIC of Radiology”, Ministry of Health of Russia, 2022. 239 p. (In Russ.).
3. Toro J.R., Travis L.B., Wu H.J. et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer 2006;119(12);2922–30. DOI: 10.1002/ijc.22239
4. Coindre J.M., Terrier P., Guillou L. et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer 2001;91(10);1914–26. DOI: 10.1002/1097-0142(20010515)91:103.0.co;2-3
5. Frank G.A. Problems of morphological classification and diagnosis of soft tissue tumors. Practicheskaya oncologiya = Practical Oncology 2004;5:231–6. (In Russ.).
6. Cates J.M.M. The AJCC 8th edition staging system for soft tissue sarcoma of the extremities or trunk: a cohort study of the SEER database. J Natl Compr Cancer Netw 2018;16(2):144–52. DOI: 10.6004/jnccn.2017.7042
7. Clinical recommendations for the diagnosis and treatment of patients with soft tissue sarcoma. Clinical recommendations of the All-Russian Union of Public. (In Russ.). Available at: https://oncology-association. ru/wp-content/uploads/2020/09/sarkoma_mjagkih_tkanej.pdf.
8. Skytting B., Meis-Kindblom J.M., Larsson O. et al. Synovial sarcoma – identification of favorable and unfavorable histologic types: a Scandinavian sarcoma group study of 104 cases. Acta Orthop Scand 1999;70(6);543–54. DOI: 10.3109/17453679908997840
9. Improving outcomes for people with sarcoma. Guidance NICE. 2006. Available at: https://www.nice.org.uk/guidance/csg9.
10. Nagano S., Yahiro Y., Yokouchi M. et al. Doppler ultrasound for diagnosis of soft tissue sarcoma: efficacy of ultrasound-based screening score. Radiol Oncol Mar 2015;49(2):135–40. DOI: 10.1515/raon-2015-0011
11. Vibhakar A.M., Cassels J.A., Botchu R. et al. Imaging update on soft tissue sarcoma. J Clin Orthop Trauma 2021;22:101568. DOI: 10.1016/j.jcot.2021.101568
12. Roberts C.C., Kransdorf M.J., Beaman F.D. et al. ACR appropriateness Criteria follow-up of malignant or aggressive musculoskeletal tumors. J Am Coll Radiol 2016;13(4):389–400. DOI: 10.1016/j.jacr.2015.12.019
13. Bar-Shalom R., Valdivia A.Y., Blaufox M.D. et al. PET imaging in oncology. Semin Nucl Med 2000;30(3):150–85. DOI: 10.1053/snuc.2000.7439
14. Sarikaya I., Sarikaya A. Assessing PET parameters in oncologic 18F-FDG studies. J Nucl Med Technol 2020;48(3):278–82. DOI:10.2967/jnmt.119.236109
15. Younis M.H., Abu-Hijleh H.A., Aldahamsheh O.O. et al. Meta-analysis of the diagnostic accuracy of primary bone and soft tissue sarcomas by 18F-FDG-PET. Med Princ Pract 2020;29(5):465–72. DOI: 10.1159/000505651
16. Chen L., Wu X., Ma X. et al. Prognostic value of 18F-FDG PET-CTbased functional parameters in patients with soft tissue sarcoma: a meta-analysis. Medicine 2017;96(6):5913. DOI: 10.1097/MD.0000000000005913
17. Hui J.Y. Epidemiology and etiology of sarcomas. Surgical clinics 2016;96(5):901–14. DOI: 10.1016/j.suc.2016.05.005
18. Etchebehere E.C., Hobbs B.P., Milton D.R. et al. Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2016;43(5):860–70. DOI: 10.1007/s00259-015-3242-z
19. Macpherson R.E., Pratap S., Tyrrell H. et al. Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. Clin Sarcoma Res 2018;8:9. DOI:10.1186/s13569-018-0095-9
20. Rakheja R., Makis W., Skamene S. et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. Am J Roentgenol 2012;198(6):1409–16. DOI:10.2214/ajr.11.7560
21. Katal S., Gholamrezanezhad A., Kessler M. et al. PET in the diagnostic management of soft tissue sarcomas of musculoskeletal origin. PET Clin 2018;13(4):609–21. DOI:10.1016/j.cpet.2018.05.011
22. Schulte M., Brecht-Krauss D., Hamer B. et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is noninvasive determination of biological activity possible? Eur J Nucl Med 1999;26(6):599–605. DOI: 10.1007/s002590050427
23. Gabriel M., Rubello D. 18F-FDG PET-CT in soft tissue sarcomas. Nucl Med Commun 2015;37(1):3–8. DOI:10.1097/mnm.0000000000000407
24. Hain S.F., O’Doherty M.J., Bingham J. et al. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun 2003;24(11):1139–43. DOI: 10.1097/00006231-200311000-00003
25. Fuglø H.M., Jørgensen S.M., Loft A. et al. The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of highgrade bone and soft tissue sarcoma. Eur J Nucl Med Mol Imaging 2012;39(9):1416–24. DOI: 10.1007/s00259-012-2159-z
26. Annovazzi A., Rea S., Zoccali C. et al. Diagnostic and clinical impact of 18F-FDG PET/CT in staging and restaging soft-tissue sarcomas of the extremities and trunk: mono-institutional retrospective study of a sarcoma referral center. J Clin Med 2020;9(8):2549. DOI: 10.3390/jcm9082549
27. Noebauer-Huhmann I.M., Weber M.A., Lalam R.K. et al. Soft tissue tumors in adults: ESSR-approved guidelines for diagnostic imaging. Semin Musculoskelet Radiol 2015;19(5):475–82. DOI: 10.1055/s-0035-1569251
28. Roberge D., Vakilian S., Alabed Y.Z. et al. FDG PET/CT in initial staging of adult soft-tissue sarcoma. Sarcoma 2012;2012:960194. DOI:10.1155/2012/960194
29. Hagi T., Nakamura T., Sugino et al. Is FDG-PET/CT useful for diagnosing pulmonary metastasis in patients with soft tissue sarcoma? Anticancer Res 2018;38(6):3635–9. DOI: 10.21873/anticanres.12638
30. Keung E.Z., Chiang Y.J., Voss R.K. et al. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 2018;44(1):170–7. DOI: 10.1016/j.ejso.2017.11.014
31. Lim H.J., Johnny Ong C.A., Tan J.W. et al. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: a systematic review. Crit Rev Oncol Hematol 2019;143: 1–13. DOI:10.1016/j.critrevonc.2019.07.002
32. Tanaka K., Ogawa G., Mizusawa J. et al. Prospective comparison of various radiological response criteria and pathological response to preoperative chemotherapy and survival in operable high-grade soft tissue sarcomas in the Japan Clinical Oncology Group study JCOG0304. World J Surg Oncol 2018;16(1):1–8. DOI: 10.1186/s12957-018-1462-y
33. Gui C., Morris C.D., Meyer C.F. et al. Characterization and predictive value of volume changes of extremity and pelvis soft tissue sarcomas during radiation therapy prior to definitive wide excision. Radiat Oncol J 2019;37(2):117–26. DOI: 10.3857/roj.2018.00549
34. Bludov A.B., Zamogilnaya Ya.A., Nered A.S. et al. Basic principles of dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the preoperative chemotherapy in patients with bone and soft tissue sarcomas. Sarkomy kostej, myagkikh tkanej i opukholi kozhi = Bone and soft tissue sarcomas, tumors of the skin 2011(4):41–50. (In Russ.).
35. Benz M.R., Czernin J., Allen-Auerbach M.S. et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clinic Cancer Res 2009;15(8);2856–63. DOI: 10.1158/1078-0432.ccr-08-2537
36. Schuetze S.M., Rubin B.P., Vernon C. et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103(2):339–48. DOI: 10.1002/cncr.20769.
37. Evilevitch V., Weber W.A., Tap W.D. et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008;14(3):715–20. DOI: 10.1158/1078-0432.ccr-07-1762
38. Ezuddin N.S., Pretell-Mazzini J., Yechieli R.L. et al. Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy. Skeletal Radiol 2018;47(12):1595–606. DOI: 10.1007/s00256-018-2965-x
39. Benz M.R., Crompton J.G., Harder D. PET/CT variants and pitfalls in bone and soft tissue sarcoma. Semin Nucl Med 2021;51(6):584–92. DOI: 10.1053/j.semnuclmed.2021.06.009.
40. Piperkova E., Mikhaeil M., Mousavi A. et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med 2009;34(3):146–50. DOI: 10.1097/RLU.0b013e3181966f9d
41. Ibraheem A.L., Buck A.K., Benz M.R. et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer 2013;119(6):1227–34. DOI: 10.1002/cncr.27866
42. Ranieri G., Mammi M., Donato E. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol 2014;89(2):322–39. DOI: 10.1016/j.critrevonc.2013.08.012
43. Larson S.M., Erdi Y., Akhurst T. et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999;2(3):159–71. DOI: 10.1016/s1095-0397(99)00016-3
44. Choi E.S., Ha S.G., Kim H.S. et al. Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging 2013;40(12):1836–42. DOI: 10.1007/s00259-013-2511-y
45. Hong S., Lee S.E., Choi Y.L. et al. Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters. Skeletal Radiology 2014;43(5):641–8. DOI:10.1007/s00256-014-1832-7
46. Chang K.J., Lim I., Park J.Y. et al. The role of 18F-FDG PET/CT as a prognostic factor in patients with synovial sarcoma. Nucl Med Mol Imaging 2015;49(1):33–41. DOI: 10.1007/s13139-014-0301-5
Review
For citations:
Koroleva E.S., Pronin A.I., Mikhailov A.I., Odzharova A.A., Sushentsov E.A., Bokhyan B.Y., Krylov A.S. The role of positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose in the diagnosis of soft tissue sarcomas. Bone and soft tissue sarcomas, tumors of the skin. 2022;14(4):63-70. (In Russ.) https://doi.org/10.17650/2782-3687-2022-14-4-63-70
Views:
273
Email this article 
